How BeReal plans to recapture its 2022 viral moment
BeReal, the buzziest app of 2022, is planning a comeback.
Ben Moore, BeReal's managing director, told BI how the app plans to recapture its viral moment.
This article is part of " CMO Insider," a series on marketing leadership and innovation.
BeReal is plotting a comeback.
In 2022, the app was the toast of the consumer tech world.
It won "App of the Year" at Apple's App Store awards. SNL even featured the app in a skit, making fun of its signature "Time to BeReal" notification, which prompts users to quickly snap a photo with their phone's front and back-facing cameras.
But it didn't take long for the hype to fade. Usage and downloads tapered off after its peak, and the app was sold to the French app and gaming company Voodoo Games for 500 million euros last summer.
One year later, BeReal is preparing its comeback.
Speaking to Business Insider at the Cannes Lions advertising festival in France, BeReal managing director Ben Moore said the app is adding new features and ramping up marketing as it looks to get lapsed users to return and find new ones.
"We have people that are committed to building the next big thing with BeReal," Moore said. "We can make something that really answers the demands of Gen Z, who are sick and tired of the filters, of the lenses, of the social pressure of posting something that's not going to get them the level of views and likes they would want."
Time to ReLaunch
According to the market intelligence firm Sensor Tower, BeReal has amassed more than 126 million downloads since its launch in 2020.
In the year-to-date, though, the app was downloaded about 4.5 million times globally, down 50% year-on-year and 7% versus the same period in 2023, "as heightened competition from legacy social media platforms and short-form video platforms has pressured adoption," said Abraham Yousef, senior insights analyst at Sensor Tower.
Moore said the app currently has around 40 million active users, and that Japan, France, and the US are its biggest markets.
BeReal is hoping to reignite interest in the app by investing in advertising, largely on other apps owned by Voodoo Games, and also through tactics like using micro ambassadors at college campuses, or sponsoring parties that require guests to download the app to gain entry.
"We really want to bring back the social aspect of what social media was built for," Moore said.
BeReal is also adding new features like "nearby," which lets people discover other users local to them. Another feature analyzes the photos users take to recommend other people who post similar kinds of pictures, such as of their dogs, travels, or cooking.
Moore said BeReal, which introduced ads last year, also wants to prioritize ads on the app that look and feel more like users' own posts.
Gareth Jones, chief growth officer of the creative agency Ralph, said BeReal's success would hinge on living up to the promise of its name and playing into the idea of being an antidote to modern social media.
"We live in an age of asinine algorithms and addictive social garbage," Jones said. "If BeReal can bring an element of humanity back to the social media space, this will create more success than any amount of marketing."
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Miami Herald
27 minutes ago
- Miami Herald
Coral Gables restaurants are luring diners with deals during the slow summer days
Where do you eat when you want a bargain but it's not yet time for Miami Spice? You go to Coral Gables and take part in Taste the Gables Restaurant Month. Throughout the month of July, more than 70 restaurants in the Gables will offer specially priced lunch and dinner menus as well as other promotional deals. The list of participants includes culinary favorites like Niven Patel's Italian restaurant Erba, which was hailed by Esquire magazine as one of the best new restaurants of 2023; Thomas Keller's French Bouchon Bistro; the Michelin-recognized Asian spot Kojin; and the Michelin-starred omakase counter Shingo. You'll also find a couple of Michelin Bib Gourmands on the list, too, like Zitz Sum and Bachour. A Bib Gourmand designates a restaurant with good food that's affordable. Lunch menus starting at $30, while dinners run from $45-$60 for three courses. Belkys Perez, economic development director for the city, said that the program aims to highlight the culinary talent in the area as well as help out restaurants that usually see business drop off during the long, hot Miami summer. 'Taste the Gables gives residents and visitors alike a reason to explore our restaurants, try new flavors and support local businesses during a traditionally slower time of year,' she said. The promotion is also way for restaurants to encourage locals to to try their cuisine. 'We are proud and excited to be part of Taste the Gables and share our Journey of the Hispanic flavors with our community,' said Juan Diego Canahuati, who owns the Latin restaurant Arcano with his wife Nicole. 'There's no better place than this event, where we are celebrating local flavors and culinary artistry, to showcase and give a taste of our passion for pan-Hispanic soul food.' Taste the Gables When: July 1-31 Where: Restaurants throughout Coral Gables List of participating restaurants and menus:


Business Upturn
3 hours ago
- Business Upturn
PTC Industries shares up 1.8% on strong military partnership outlook
By Aman Shukla Published on June 30, 2025, 11:03 IST PTC Industries shares rose 1.8% in early trade after management highlighted the strategic importance of its latest Memorandum of Understanding (MoU) with French aerospace major Safran. Unlike their earlier MoU focused on civil aviation, the new agreement targets military operations—marking a major shift in scope. Chairman & MD Sachin Agarwal told CNBC-TV18 that the company expects significant growth from this MoU, which aligns with other ongoing defense-related investments. He added that PTC Industries anticipates operating margins in the mid-to-high 20% range for FY26. Agarwal also revealed that the company plans to sign several similar agreements over the next six months, indicating a strong pipeline of defense sector collaborations. PTC Industries shares opened at ₹15,080.00 and hit a high of ₹15,488.00 during the day, while the low stood at ₹15,013.00. The stock is trading well above its 52-week low of ₹9,756.30 but remains below the 52-week high of ₹17,995.00. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at


Business Wire
4 hours ago
- Business Wire
CARMAT Announces Filing Today for Insolvency and Requesting Being Placed in Receivership
PARIS--(BUSINESS WIRE)--Regulatory News: CARMAT (FR0010907956, ALCAR), designer and developer of the world's most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure (the ' Company ' or ' CARMAT '), today announces filing for insolvency 1 and requesting to be placed in receivership 2 to the Versailles Economic Affairs Court 3, as well as the suspension of CARMAT shares trading, starting June 30, 2025, before stock market opening. Insolvency filing and request to be placed in receivership On June 20, 2025, CARMAT announced in a press release being at risk of insolvency as early as the end of June 2025 unless managing before then, to secure additional cash of at least €3.5 million. Despite its continued efforts, the Company has not managed at this stage, to secure neither additional cash nor new financing. Given this, the Company will today file for insolvency and request to be placed in receivership to the Versailles Economic Affairs Court ('the Court'). The Court will rule on this request, following a hearing expected in the coming days. As a reminder, according to its current business plan and assuming 'business as usual' situation, the Company estimates its funding requirements over the next 12 months at approximately €35 million, including approximately €20 million by the end of December 2025. Suspension of CARMAT shares trading (ISIN code: FR0010907956, Ticker: ALCAR) Pending the Court's decision, CARMAT has asked Euronext to suspend the trading of its shares starting on June 30, 2025, before the stock market opens. The Company anticipates this suspension to be lifted once the Court's decision has been rendered and communicated to the market. Next steps Pending the Court's decision, CARMATS's operations carry-on and the Company continues to actively explore all options to ensure the continuation of its business activities. The Company believes that the opening of a receivership procedure would be the most appropriate framework to facilitate this continuation. More generally, whatever the Court's decision, the Company will endeavor to provide continuous support to patients who currently benefit from its Aeson® artificial heart. Press releases will be issued regularly as the Company's situation evolves and the proceedings progress. About CARMAT CARMAT is a French MedTech that designs, manufactures and markets the Aeson ® artificial heart. The Company's ambition is to make Aeson ® the first alternative to a heart transplant, and thus provide a therapeutic solution to people suffering from end-stage biventricular heart failure, who are facing a well-known shortfall in available human grafts. The world's first physiological artificial heart that is highly hemocompatible, pulsatile and self-regulated, Aeson ® could save, every year, the lives of thousands of patients waiting for a heart transplant. The device offers patients quality of life and mobility thanks to its ergonomic and portable external power supply system that is continuously connected to the implanted prosthesis. Aeson ® is commercially available as a bridge to transplant in the European Union and other countries that recognize CE marking. Aeson ® is also currently being assessed within the framework of an Early Feasibility Study (EFS) in the United States. Founded in 2008, CARMAT is based in the Paris region, with its head offices located in Vélizy-Villacoublay and its production site in Bois-d'Arcy. The Company can rely on the talent and expertise of a multidisciplinary team of circa 200 highly specialized people. CARMAT is listed on the Euronext Growth market in Paris (Ticker: ALCAR / ISIN code: FR0010907956). For more information, please go to and follow us on LinkedIn. Disclaimer This press release and the information it contains do not constitute an offer to sell or subscribe, nor a solicitation of an offer to buy or subscribe, for CARMAT shares in any country. This press release may contain forward-looking statements regarding the Company's objectives and outlook. These forward-looking statements are based on the current estimates and anticipations of the Company's management and are subject to risk factors and uncertainties, including those described in its Universal Registration Document filed with the French Financial Markets Authority (Autorité des marchés financiers) (the 'AMF') under number D.25-0345 (the ' 2024 Universal Registration Document '), available free of charge on the websites of CARMAT ( and the AMF ( Readers' attention is particularly drawn to the fact that the Company's current cash runway extends only until the end of June 2025, and that CARMAT is therefore facing a very high risk of default, including in the very short term. The Company is also exposed to other risks and uncertainties, such as its ability to implement its strategy, the pace of development of its production and sales, the progress and results of ongoing or planned clinical trials, technological developments, the competitive landscape, regulatory changes, industrial risks, and all risks related to the management of the Company's growth. Forward-looking statements mentioned in this press release may not be achieved due to these factors or other unknown risks and uncertainties, or risks that the Company does not currently consider to be material or specific. Aeson® is an active implantable medical device commercially available in the European Union and other countries recognising the CE mark. The Aeson® total artificial heart is intended to replace the ventricles of the native heart and is indicated as a bridge to transplant in patients with end-stage biventricular heart failure (Intermacs classes 1-4) who cannot benefit from maximal medical therapy or a left ventricular assist device (LVAD) and who are likely to benefit from a heart transplant within 180 days of implantation. The decision to implant and the surgical procedure must be carried out by healthcare professionals trained by the manufacturer. The documentation (clinician's manual, patient's manual and alarm booklet) must be read carefully to learn about the characteristics of Aeson® and the information required for patient selection and proper use (contraindications, precautions, side effects) of Aeson®. In the United States, Aeson® is currently only available as part of a feasibility clinical trial approved by the Food & Drug Administration (FDA).